What changed: Non-metastatic castration-resistant prostate cancer
Every dated change on the records linked to Non-metastatic castration-resistant prostate cancer, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Approval1Trial result1Milestone4This record1
September 2026 · 1
2020 · 1
2019 · 1
2018 · 3
- 2018ApprovalEnzalutamideEnzalutamide approved in US
Non-metastatic CRPC
- 2018Trial resultPROSPERPROSPER reported
Enzalutamide lengthened metastasis-free survival and, with longer follow-up, overall survival compared with placebo; approved in July 2018.
- 2018MilestoneEnzalutamideSPARTAN and PROSPER: apalutamide and enzalutamide approved for nmCRPC
A milestone in how this cancer is treated.